A decision from the FDA is anticipated by 30 November 2026.

Izalontamab brengitecan more than doubled PFS compared with chemotherapy ...

Celcuity’s gedatolisib doubled progression-free survival versus standard of care in certain patients with advanced breast ...

The data show that the drug, in combination with others, reduced the risk of disease progression or death by about 50%. ・Celcuity said the results mark the first time a Phase 3 trial has shown one ...

Gedatolisib could “establish a new standard of care” for PIK3CA-mutated breast cancer, an investigator said, but the results nonetheless appeared to disappoint investors.

Percheron Therapeutics Ltd (ASX:PER, OTC:PERCF) has unveiled new preclinical data suggesting its lead cancer therapy HMBD-002 ...

Where a woman lives significantly affects whether her breast cancer is diagnosed at an early or late stage, according to a national analysis published in the Journal of the American College of ...

Your breast cancer stage plays an important role in your treatment choices. For stages II and III, treatment often involves some combination of chemotherapy, radiation therapy, surgery, targeted drugs ...

By Christy Santhosh June 2 (Reuters) - Celcuity shares slumped 25%, set for their biggest one-day decline, on Tuesday after its experimental breast cancer treatment extended the period of time a ...

Giredestrant has the potential to become a new standard-of-care in the adjuvant setting; more than 90% of ER-positive breast cancer cases are diagnosed at an early-stage (I-III) The FDA has set a ...

Jessie J shared the bombshell news that she has breast cancer on Instagram on Tuesday, telling fans that it was caught “early” but she planned to “disappear for a bit” while she recovers from surgery.